Skip to main content

Advertisement

SpringerLink
Log in

Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease

  • Prostate Cancer (S Prasad, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Androgen deprivation therapy (ADT) is a mainstay of treatment for advanced prostate cancer. Several studies have reported an association between ADT and an increase in cardiovascular events, especially in those receiving gonadotropin-releasing hormone (GnRH) agonists compared to GnRH antagonists. We review the body of literature reporting the association of ADT and cardiovascular morbidity, and discuss the proposed mechanism of cardiovascular disease due to ADT including metabolic changes that may promote atherosclerosis and local hormonal effects that may increase plaque rupture and thrombosis.

Recent Findings

GnRH agonists appear to increase the risk of cardiovascular morbidity by 20–25% in men on these agents compared those who do not receive ADT. GnRH antagonists may appear to have halve this risk while improving PSA progression-free survival.

Summary

GnRH antagonists may be superior to GnRH agonists for patients with significant cardiovascular disease, significant metastatic disease burden, or severe lower urinary tract symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. WHO. Globocan 2012. http://globocan.iarc.fr/Default.aspx

  2. Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859–64.

    Article  PubMed  Google Scholar 

  3. Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg. 1942;115(6):1192–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in OncologyTM. Prostate cancer. National Comprehensive Cancer Network: Fort Washington, PA, Version 1. 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed January 2017.

  5. Mariani A, Glover M, Arita S. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. J Urol. 2001;165(1):104–7.

    Article  CAS  PubMed  Google Scholar 

  6. Drudge-Coates L. GnRH blockers: a changing paradigm in the management of prostate cancer. Int J Urol Nurs. 2009;3:85–92.

    Article  Google Scholar 

  7. Klotz L, Boccon–Gibod L, Shore N, Andreou C, Persson B, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–8.

    Article  CAS  PubMed  Google Scholar 

  8. Shore N. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. 2013;5:11–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Keating N, O’Malley A, Smith M. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;23:4448–56.

    Article  Google Scholar 

  10. Tsai H, D’Amico A, Sadetsky N, Chen M, Carrol P. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–24.

    Article  PubMed  Google Scholar 

  11. Saigal C, Gore J, Krupski T, Hanley J, Schonlau M, Litwin M. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–500.

    Article  CAS  PubMed  Google Scholar 

  12. D’Amico A, Denham J, Crook J, Chen M, Goldhaber S, Lamb D, Joseph D, Tai K, Malone S, Ludgate C, Steigler A, Kantoff P. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–5.

    Article  PubMed  Google Scholar 

  13. D’Amico A, Chen M, Renshaw A, Loffredo M, Kantoff P. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 2008;113:3290–7.

    Article  PubMed  Google Scholar 

  14. Levine G, D’Amico A, Berger P, Clark P, Eckel R, Keating N, Milani R, Sagalowsky A, Smith M, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. A science advisory from the American Heart Association, American Cancer Society, and American Urologic Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121:833–40.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Studer U, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram S, Debois M, Collette L. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24:1868–76.

    Article  PubMed  Google Scholar 

  16. Efstathiou J, Bae K, Shipley W, Hanks G, Pilepich M, Sandler H, Smith M. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol. 2008;54:816–23.

    Article  CAS  PubMed  Google Scholar 

  17. Roach III M, Bae K, Speight J, Wolkov H, Rubin P, Lee R, Lawton C, Valicenti R, Grignon D, Pilepich M. Short-term neoadjuvant androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–91.

    Article  PubMed  Google Scholar 

  18. Efstathiou J, Bae K, Shipley W, Hanks G, Pilepich M, Sandler H, Smith M. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009;27:92–9.

    Article  PubMed  Google Scholar 

  19. Bolla M, de Reijke T, Van Tienhoven G, Van den Bergh A, Oddens J, Poortmans P, Gez E, Kil P, et al. EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–27.

    Article  CAS  PubMed  Google Scholar 

  20. • Klotz L, Miller K, Crawford D, Shore N, Tombal B, Karup C, Malmberg A, Persson BE. Disease control outcomes from analysis of pooled individual patient data from five comparative randomized clinical trials of Degarelix versus lutenizing hormone-releasing hormone agonists. Eur Urol. 2014;66:1101–8. Post hoc analysis of five prospective phase 3 or 3b randomized trials comparing the efficacy of GnRH agonists against an antagonist which showed improved overall survival and adverse events with degarelix

    Article  CAS  PubMed  Google Scholar 

  21. •• Albertsen P, Klotz L, Bertrand T, Grady J, Olesen T, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565–73. Post hoc analysis of six prospective randomized trials comparing the efficacy of GnRH agonists against an antagonist which found that GnRH antagonists halved the number of cardiac events experienced by men with pre-existing cardiovascular disease compared to GnRH agonists

    Article  CAS  PubMed  Google Scholar 

  22. Huhtaniemi I, White R, McArdle C, Persson B. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab. 2009;20:43–50.

    Article  CAS  PubMed  Google Scholar 

  23. Varenhorst E, Wallentin L, Carlstrom K. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand J Urol Nephrol. 1982;16:31–6.

    Article  CAS  PubMed  Google Scholar 

  24. Millar R, Lu Z, Pawson A, Flanagan C, Morgan K, Maudsley S. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004 Apr;25(2):235–75.

    Article  CAS  PubMed  Google Scholar 

  25. Harris W, Mostaghel E, Nelson P, Mongomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Calais da Silva F, Bono A, Whelan P, Brausi M, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55(6):1269–77.

    Article  CAS  PubMed  Google Scholar 

  27. Keating N, O’Malley A, Freeland S, Smith M. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm Accessed January 2017

  29. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol. 2010;28:3448–56.

    Article  PubMed  Google Scholar 

  30. Martin-Merino E, Johansson S, Morris T, Garcia RL. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested-case-control study in UK primary care. Drug Saf. 2011;34(11):1061–77.

    Article  PubMed  Google Scholar 

  31. Azoulay L, Yin H, Bernayoun S, Renoux C, Boivin J, Suissa S. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol. 2011;60(6):1244–50.

    Article  CAS  PubMed  Google Scholar 

  32. Hu J, Williams S, O’Malley A, Smith M, Nguyen P, Keating N. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012;61(6):1119–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Jespersen C, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65(4):704–9.

    Article  CAS  PubMed  Google Scholar 

  34. • O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–51. Multivariate analysis of a cohort of 41,362 men with prostate cancer on ADT compared to age-matched prostate cancer-free men which found a 21% increased risk of cardiovascular disease in men on GnRH agonists compared with the comparison cohort. This risk was highest in the first 6 months of therapy

    Article  PubMed  Google Scholar 

  35. Alibhai S, Duong-Hua M, Sutradhar R, Fleshner N, Warde P, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27:3452–8.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, et al. The impact of the androgen deprivation therapy on the risk of coronary heart disease in patients with non-metastatic prostate cancer: a population-based study. BJU Int. 2014;114(6b):E82–9.

    Article  CAS  PubMed  Google Scholar 

  37. •• Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One. 2014;9(9):–e107516. Meta-analysis of six population-based observational studies comparing ADT versus control which found that GnRH therapy is associated with an increased risk of cardiovascular disease and cardiovascular mortality

  38. •• Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating N, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68:386–96. Meta-analysis of eight observational studies comparing ADT with control which found a relative risk of 1.38 for non-fatal cardiovascular disease in me non-GnRH agonist therapy compared to men not treated with ADT

    Article  PubMed  Google Scholar 

  39. Punnen S, Cooperberg M, Sadetsky N, Carroll P. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011;29(26):3510–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Wilcox C, Jautto A, Steigler A, Denham J. Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term. Oncology. 2012;82(1):56–8.

    Article  CAS  PubMed  Google Scholar 

  41. Nguyen P, Je Y, Schutz F, Hoffman K, Hu J, Parekh A, Beckman J, Choueiri T. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–66.

    Article  CAS  PubMed  Google Scholar 

  42. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844–50.

    Article  CAS  PubMed  Google Scholar 

  43. Jacobson J, Nisula B, Steinberg A. Modulation of the expression of murine lupus by gonadotropin-releasing hormone analogs. Endocrinology. 1994;134:2516–23.

    Article  CAS  PubMed  Google Scholar 

  44. Chen H, Jueng E, Stephenson M, Leung P. Ribonucleic acids that are regulated by GnRH in vitro. Endocrinol Metab. 1999;84:743–50.

    CAS  Google Scholar 

  45. Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F, Bouloux P. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol. 2005;142:103–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Grasso G, Massai L, De Leo V, Muscettola M. The effect of LHRH and TRH on human interferon-gamma production in vivo and in vitro. Life Sci. 1998;62(22):2005–14.

    Article  CAS  PubMed  Google Scholar 

  47. Andersson J, Libby P, Hansson G. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134(1):33–46.

    Article  CAS  PubMed  Google Scholar 

  48. Dixit V, Yang H, Udhayakumar V, Sridaran R. Gonadotropin-releasing hormone alters the t helper cytokine balance in the pregnant rat. Biol Reprod. 2003;68:2215–21.

    Article  CAS  PubMed  Google Scholar 

  49. Smith M, Klotz L, van der Meulen E, Colli E, Tanko L. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol. 2011;186:1935–842.

    Google Scholar 

  50. Tombal B, Miller K, Boccon-GIbod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010;57:836–42.

    Article  CAS  PubMed  Google Scholar 

  51. Crawford E, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011;186:889–97.

    Article  CAS  PubMed  Google Scholar 

  52. • Crawford E, Shore N, Moul J, Tombal B, et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology. 2014;83(5):1122–8. The 5-year results from the cross-over trial of CS21 where patients receiving leuprolide were crossed over to degarelix after one year which showed a durable PSA progression-free survival benefit for degarelix over leuprolide at 5 years

    Article  PubMed  Google Scholar 

  53. Hopmans S, Duivenvoorden W, Werstuck G, Klotz L, Pinthus J. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol. 2014;32(8):1126–34.

    Article  CAS  PubMed  Google Scholar 

  54. Radu A, Pichon C, Camparo P, Antoine M, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010;363(17):1621–30.

    Article  CAS  PubMed  Google Scholar 

  55. Robinson D, Sandblom G, Johansson R, Garmo H, Stattin P, Mommsen S, et al. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J Urol. 2008;179:117–22.

    Article  CAS  PubMed  Google Scholar 

  56. Schrӧder F, Tombal B, Miller K, Boccon-Gibod L, Shore N, Crawford E, et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2009;106:182–7.

    Article  Google Scholar 

  57. Axcrona K, Aaltomaa S, Da Silva C, et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int. 2012;110:1721–8.

    Article  CAS  PubMed  Google Scholar 

  58. Mason M, Maldonado P, Steidle C, et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptoms relief and quality of life improvement in men with intermediate–to high-risk prostate cancer: a randomized non-inferiority trial of degarelix versus goserelin plus bicalutamide. Clin Oncol. 2013;25:190–6.

    Article  CAS  Google Scholar 

  59. Anderson J, Al-Ali G, Wirth M, et al. Degarelix versus goserelin (+antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT 00831233). Urol Int. 2013;90:321–8.

    Article  PubMed  Google Scholar 

  60. Bono A, Salvadore M, Celato N. Gonadotropin-releasing hormone receptors in prostate tissue. Anal Quant Cytol Histol. 2002;24:221–7.

    PubMed  Google Scholar 

  61. Rick F, Schally A, Block N, et al. LHRH antagonist cetorelix reduces prostate size and gene expression of proinflammtory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate. 2001;71:736–47.

    Article  Google Scholar 

  62. Giuliano F, Behr-Roussel D, Oger S, et al. Ozarelix, an LHRH antagonist, exerts a direct relaxing effect on human prostate in vitro. J Urol. 2009;181:693.

    Article  Google Scholar 

  63. Hatoum H, Crawford E, Nielsen S, et al. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2013;13:261–70.

    Article  PubMed  Google Scholar 

  64. Lee D, Porter J, Gladwell D, Brereton N, Nielsen S. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom. J Med Econ. 2014;17(4):233–47.

    Article  PubMed  Google Scholar 

  65. Kelly D, Jones T. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217:24–45.

    Google Scholar 

  66. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165:687–701.

    Article  CAS  PubMed  Google Scholar 

  67. Zareba P, Duivenvoorden W, Leong D, Pinthus J. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8(2):118–29.

    Article  CAS  PubMed  Google Scholar 

  68. Smith M. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep. 2008;9(3):197–202.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Smith M, Finkelstein J, McGovern F, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599–603.

    Article  CAS  PubMed  Google Scholar 

  70. Bourghardt J, Wilhelmson A, Alexandeson C, De Gendt K, Verhoeven G, Krettek A, et al. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology. 2010;151:5428–37.

    Article  CAS  PubMed  Google Scholar 

  71. Falk E. Mophologic feature of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 1989;3:114–20.

    Article  Google Scholar 

  72. Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res. 2009;50(suppl):S352–237.

    PubMed  PubMed Central  Google Scholar 

  73. Hansson G, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–12.

    Article  CAS  PubMed  Google Scholar 

  74. Bhatia N, Santos M, Jones L, Beckman J, Penson D, Morgans A, Moslehi J. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133:537–41.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Jacobs E, Newton CC, Stevens V, Campbell P, Freedland S, Gapstur S. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol. 2014;32:3716–22.

    Article  CAS  PubMed  Google Scholar 

  76. Conteduca V, Di Lorenzo G, Tartarone A, Aieta M. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Ocol Hematol. 2013;8:2–51.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas St., CSB 644, Charleston, SC, USA

    Alyssa K. Greiman & Thomas E. Keane

Authors
  1. Alyssa K. Greiman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas E. Keane
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alyssa K. Greiman.

Ethics declarations

Conflict of Interest

Alyssa K. Greiman declares no potential conflicts of interest. Thomas E. Keane reports consultancies for Ferring, Bayer, and Jannsen.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Prostate Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greiman, A.K., Keane, T.E. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Curr Urol Rep 18, 41 (2017). https://doi.org/10.1007/s11934-017-0688-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-017-0688-5

Keywords

Search

Navigation